Western Blot vs Modified Two-Tier Testing in Lyme Disease

Quick Answer: Modified Two-Tier Testing (MTTT) replaces Western blot with two enzyme immunoassays, but both approaches have limitations—especially in early Lyme disease.

Clinical Insight: Lyme disease testing methods have evolved, but no current approach reliably detects all cases. Clinical judgment remains essential.

Is Modified Two-Tier Testing better than Western blot?

Newer Lyme disease tests were introduced to improve accuracy and simplify interpretation—but the reality is more complex.

Both traditional and newer testing methods share important limitations.

---

The 2017 Proposal to Replace Western Blot Testing

In 2017, researchers proposed replacing Western blot testing with newer methods designed to simplify and standardize diagnosis. :contentReference[oaicite:0]{index=0}

Their approach replaced the traditional two-tier algorithm (ELISA followed by Western blot) with two enzyme immunoassays:

• Whole-cell sonicate (WCS) EIA
• C6 peptide EIA
• VlsE chemiluminescence immunoassay (CLIA)

This approach—called Modified Two-Tier Testing (MTTT)—was designed to improve early detection and reduce subjectivity in interpretation.

---

Why There Was Resistance to Replacing Western Blot

Western blot had known limitations, including subjective band interpretation and reduced sensitivity in early infection.

However, it had been the standard diagnostic method for decades and provided antigen-specific information that many clinicians relied on.

The question was not whether Western blot was imperfect—but whether the replacement was truly better.

---

The Sensitivity Problem With Both Approaches

Both testing strategies show limitations:

• Traditional two-tier testing has limited sensitivity in early Lyme disease
• Modified Two-Tier Testing shows modest improvement but is based on smaller datasets

Neither approach reliably detects all cases—especially early in infection.

This reflects a fundamental issue:

Both tests depend on antibody production, which takes time to develop.

---

What Actually Happened: FDA Clearance and Clinical Use

Beginning in 2019, certain MTTT protocols received FDA clearance.

However, Western blot testing was not eliminated.

Both testing methods remain in use today.

Clinicians may choose one approach over another depending on clinical context.

---

Current Reality: Two Options, Same Limitations

Western blot provides antigen-specific band data, while MTTT offers greater standardization.

However:

• Both detect antibodies—not active infection
• Both may be negative early in disease
• Both may miss complex or persistent cases

Changing the test does not change the biology of infection.

---

Why Clinical Judgment Still Matters

This reflects a broader principle:

Laboratory testing supports diagnosis—but does not replace clinical judgment.

Many patients present with symptoms before antibodies are detectable.

Others may remain seronegative despite ongoing illness.

Understanding symptom patterns is critical. See Lyme disease symptoms guide.

This diagnostic uncertainty is part of why Lyme disease tests the limits of medicine.

---

Frequently Asked Questions

Is Modified Two-Tier Testing better than Western blot?
MTTT offers standardization but does not eliminate key limitations. Both methods have similar constraints.

Can I still get Western blot testing?
Yes. Western blot remains available and is still used in clinical practice.

Why don’t Lyme tests work well early?
Both rely on antibodies, which take time to develop after infection.

What if my test is negative but I have symptoms?
Negative testing does not rule out Lyme disease, especially in early infection.

---

Clinical Takeaway

Western blot and Modified Two-Tier Testing both have important limitations.

While testing methods have evolved, neither approach reliably detects all cases—particularly early in disease.

Clinical judgment based on symptoms and exposure history remains essential.

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention